Skip to main content

Media Alert – Investment Announcement!

March 16th, 2022 – Birmingham, Michigan – CitySide Ventures and GLAF announce adding Hera Biotech to its portfolio of companies.

Hera Biotech, Inc. was formed to apply advances in biotechnology to address unmet needs in the field of women’s health and specifically, in reproductive medicine. Hera began operations in January of 2020 as a Delaware “C” Corporation with headquarters in San Antonio, TX. Hera’s initial goal is to commercialize the MetriDx™, a novel, non-surgical method for the definitive and early diagnosis of endometriosis.

Endometriosis is estimated to affect 10-20% of women, aged 15-44 worldwide; 7-13 million in the U.S. alone. The average time a woman in the U.S. goes before receiving an endometriosis diagnosis is 7-12 years. One of the largest contributing factors to the length of time it takes for a woman to receive a diagnosis from the time she develops symptoms, is because the current method for definitive diagnosis of endometriosis is done via a laparoscopic surgery, where lesions are excised or biopsied and confirmed by histological pathology, which fails to confirm diagnosis ~50% of the time.

“Once in a while we get to be a part of a company that not only presents a greater opportunity for us as investors but solves a big problem needing to be solved that impacts millions of people around the world. Hera Biotech is one of those companies. We are very lucky to be a part of this company and  are privileged to be able to support its mission. ”  – Doron York – Chairman/CEO  at CitySide Ventures  

CitySide Ventures is to become a premier Investment group committed to taking Michigan Angel investing to a new level by building a network of active, progressive, and innovative investors committed to turning Michigan into a powerhouse startup ecosystem.

For more information about Birmingham Angels please visit us at

For more information about Great Lakes Angels Fund please visit us at

If you are an accredited investor and would like to schedule a private meeting,
please complete the following request form:
or contact us: or 248. 535.1306